---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-204999"
form_type: "8-K"
ticker: "OFIX"
cik: "0000884624"
company_name: "Orthofix Medical Inc."
filed_at: "2026-05-05T23:59:59+00:00"
generated_at: "2026-05-14T23:43:15.024946+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Orthofix Q1 pro forma revenue $196.4M +2.7% constant currency; reaffirms FY guidance

## Summary
- GAAP net loss $(20.9)M vs $(53.1)M prior year; adjusted EBITDA $9.7M (4.9% of pro forma sales) vs $11.4M (6.0%) prior year.
- Global Spine Fixation +6%, Therapeutic Solutions +5%, Limb Reconstruction +10% reported (+3% constant currency).
- Reaffirms FY2026 net sales $850M-$860M, adjusted EBITDA $95M-$98M, positive free cash flow.
- Cash $120.9M at March 31, 2026; plans to repay $424M 0.875% exchangeable notes due June 2026.
- Distributor transitions largely behind; expects improved commercial execution and product launches later in 2026.

## SEC filing metadata
- accession: 0001193125-26-204999
- form_type: 8-K
- ticker: OFIX
- cik: 0000884624
- company_name: Orthofix Medical Inc.
- filed_at: 2026-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/884624/000119312526204999/0001193125-26-204999-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/884624/000119312526204999/ofix-20260505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-204999
- JSON: https://secwatch.observer/filing/0001193125-26-204999.json
- Plain text: https://secwatch.observer/filing/0001193125-26-204999.txt

## Key facts
- Earnings Releases
  Orthofix Medical Inc. reported the first quarter ended March 31, 2026 results: revenue $196.7 million, net income $(20.9) million, EPS $(0.52) per share. Guidance reaffirmed.
  - Period: the first quarter ended March 31, 2026
  - Revenue: $196.7 million
  - Net income: $(20.9) million
  - EPS: $(0.52) per share
  - Guidance: reaffirmed
  - Result: reported results
  source text: measures contained within this release exclude the impact of the Company’s decision to discontinue its M6TM product lines. Highlights • First quarter 2026 reported net sales of $196.7 million, including sales from M6 artificial cervical and lumbar discs. Non-GAAP pro forma net sales of $196.4 million, excluding sales from M6 discs, increased 3% year over year on a
  evidence_url: https://www.sec.gov/Archives/edgar/data/884624/000119312526204999/0001193125-26-204999-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.